|
DDX21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.2567999999602E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.33349999999777E-05 |
| Normal-vs-Stage2 |
2.35459999999854E-05 |
| Normal-vs-Stage3 |
1.78660000005326E-06 |
| Normal-vs-Stage4 |
3.962000E-04 |
| Stage1-vs-Stage2 |
2.883200E-01 |
| Stage1-vs-Stage3 |
2.179200E-01 |
| Stage1-vs-Stage4 |
5.987400E-01 |
| Stage2-vs-Stage3 |
8.870800E-01 |
| Stage2-vs-Stage4 |
6.623600E-01 |
| Stage3-vs-Stage4 |
7.165200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.85144000000026E-05 |
| Normal-vs-AfricanAmerican |
2.978100E-02 |
| Normal-vs-Asian |
5.94910000000226E-05 |
| Caucasian-vs-AfricanAmerican |
4.925800E-01 |
| Caucasian-vs-Asian |
4.935800E-01 |
| AfricanAmerican-vs-Asian |
2.600800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.66930000009702E-08 |
| Normal-vs-Female |
2.45729999999167E-05 |
| Male-vs-Female |
2.506300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.807200E-04 |
| Normal-vs-Age(41-60Yrs) |
4.76490003009644E-09 |
| Normal-vs-Age(61-80Yrs) |
8.11000000000561E-05 |
| Normal-vs-Age(81-100Yrs) |
9.697800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.747940E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.889800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.543200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.398400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.350400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.841400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.024800E-01 |
| Classical-VS-Follicular |
1.674060E-02 |
| Classical-VS-Other |
7.530400E-02 |
| Classical-VS-Normal |
1.245400E-04 |
| Tall-VS-Follicular |
3.429600E-01 |
| Tall-VS-Other |
1.374570E-01 |
| Tall-VS-Normal |
2.517200E-03 |
| Follicular-VS-Other |
3.152200E-01 |
| Follicular-VS-Normal |
4.42359999963671E-07 |
| Other-VS-Normal |
1.218130E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.63950000137336E-08 |
| Normal-vs-N1 |
2.808200E-04 |
| N0-vs-N1 |
7.055400E-01 |
|
|
